Anglo-Swedish pharmacist AstraZeneca This Friday, the 20th, it announced promising results against a drug Govit-19 This reduces the risk of vulnerable people – such as people receiving alternative therapies or cancer patients – developing a symptomatic form of the disease. The product, which has not yet been released for use in hospitals, could become a strategy for people who need a booster beyond the vaccine.
This antibody treatment, codenamed AZD7442, has not previously proven its effectiveness in people who are already infected with the virus. But when it was administered before contacting Sars-CoV-2, the results were positive, the pharmaceutical company said in a statement.
And according to the company, this cocktail reduces the risk of reducing a symptomatic form by 77%, according to data from Phase 3, at this stage, one of the last tests, large-scale clinical trials designed to measure safety and effectiveness are being conducted. . The results have not yet been described in a scientific publication. The trials were conducted in Spain, France, Belgium, the United Kingdom and the United States, with 5,197 participants, 75% of whom had comorbidities. The treatment was given inwardly.
“With these amazing results, AZD7442 can be an important tool in our arsenal and can help people who need more than the vaccine to get back to normal life,” said Myron Levine, professor and manager at the University of Colorado in the United States. Rehearsals.
“We need other approaches for people who are not well protected by the Govt-19 vaccine,” said Mene Pangalos, a drug administrator who promised to release additional data on the tests by the end of this year. The lab states that under emergency use or treatment conditions, a file will be sent to health officials with US funding development.
AstraZeneca was one of the first to confirm the corona virus vaccine, one of the four vaccines used in the national immunization campaign in Brazil. This vaccine agent was developed in collaboration with researchers at Oxford University. /With international agencies